Rhodiola Rosea

—

evidence score

adaptogen

rhodiolagolden rootarctic root+2 more

Rhodiola rosea is a high-altitude adaptogenic herb with the strongest acute anti-fatigue evidence of any adaptogen. Active constituents are rosavins and salidroside. Multiple RCTs demonstrate improved cognitive performance under fatigue, reduced burnout symptoms, and enhanced physical endurance. Unlike ashwagandha (HPA modulation, chronic), rhodiola has acute stimulant-adjacent effects within hours. EMA (European Medicines Agency) has approved it for stress-related fatigue. SHR-5 is the most studied standardized extract.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Research Sync

Not synced yet

Dosing

Typical

400 mg

200 mgRange680 mg

Frequency1-2x/day

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~4-6 hours

OnsetAcute anti-fatigue effects within 30-60 minutes; adaptogenic effects 2-4 weeks

DurationAcute dose 4-6 hours; chronic effects persist during use

Routes

oral

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(40%)—

Quality(30%)—

Sample Size(10%)—

Consistency(10%)—

Replication(5%)—

Recency(5%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Rhodiola Rosea is currently categorized as a adaptogen compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

Inhibits MAO-A/B (mild); modulates stress kinases (JNK, AMPK); upregulates SDF-1/HSP70 stress proteins; increases serotonin, dopamine, norepinephrine availability

Practical Context

Strongest current signals

No indexed study summaries yet.